CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...
In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...
As the name suggests, the Natural Vision Improvement system is a natural solution designed to provide relief and alleviate eye-related symptoms and conditions. The system has been created by Dr.
NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...
Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...
Nanoscope Therapeutics is back with more data assessing its gene therapy that uses light-sensitive molecules to treat retinal disease. With data demonstrating vision improvement in hand, the biotech ...
Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...
Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial following a successful Phase II study of its gene therapy in Stargardt disease.
Please provide your email address to receive an email when new articles are posted on . Access to low-vision services led to significant improvement in vision and quality of life for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results